Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Rossari Biotech Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 27, 2024, 10:21 pm

Market Cap 4,412 Cr.
Current Price 797
High / Low 973/657
Stock P/E31.8
Book Value 202
Dividend Yield0.06 %
ROCE18.1 %
ROE13.2 %
Face Value 2.00
PEG Ratio2.45

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Rossari Biotech Ltd

Competitors of Rossari Biotech Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
HP Adhesives Ltd 714 Cr. 77.7 131/75.034.7 19.20.39 %17.7 %12.6 % 2.00
Haryana Leather Chemicals Ltd 42.7 Cr. 87.0 124/56.89.45 87.21.15 %8.96 %7.25 % 10.0
Hardcastle & Waud Mfg Co Ltd 58.1 Cr. 855 1,355/45130.4 6630.00 %7.00 %5.98 % 10.0
Grauer & Weil (India) Ltd 4,523 Cr. 99.8 120/64.928.2 19.20.50 %26.1 %19.6 % 1.00
DMCC Speciality Chemicals Ltd 917 Cr. 368 453/24569.2 85.40.27 %10.8 %5.68 % 10.0
Industry Average12,818.26 Cr925.8057.71173.840.32%14.09%10.82%6.44

All Competitor Stocks of Rossari Biotech Ltd

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales218231385428439435425389406411483464473
Expenses182194339381387377369335352353420400409
Operating Profit36374648525857545558646464
OPM %17%16%12%11%12%13%13%14%13%14%13%14%13%
Other Income2326311132141
Interest1125558546543
Depreciation761016171516161614151516
Profit before tax30333633343934353739454846
Tax %26%26%27%30%30%26%29%26%22%26%26%28%25%
Net Profit22252623242924262929333434
EPS in Rs4.324.464.764.144.375.214.344.665.255.305.976.236.18

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales5166007091,4831,6561,831
Expenses4384955861,2991,4331,581
Operating Profit78105124184223250
OPM %15%17%17%12%13%14%
Other Income1491368
Interest343132219
Depreciation121723486360
Profit before tax6388107136144178
Tax %28%26%25%28%26%26%
Net Profit46658098107131
EPS in Rs103.8212.8615.4517.7419.4523.66
Dividend Payout %0%4%3%3%3%2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)41.30%23.08%22.50%9.18%22.43%
Change in YoY Net Profit Growth (%)0.00%-18.23%-0.58%-13.32%13.25%

Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:29%
3 Years:37%
TTM:14%
Compounded Profit Growth
10 Years:%
5 Years:23%
3 Years:18%
TTM:19%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:-15%
1 Year:-2%
Return on Equity
10 Years:%
5 Years:16%
3 Years:14%
Last Year:13%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:46 pm

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital4101011111111
Reserves1192773987949041,0371,107
Borrowings8670874119161
Other Liabilities118118152442375401433
Total Liabilities2504715611,2551,3641,5671,711
Fixed Assets7494181607585578597
CWIP32201164798
Investments018036516353
Other Assets173338379611712880963
Total Assets2504715611,2551,3641,5671,711

Reserves and Borrowings Chart

Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +7157482915243
Cash from Investing Activity +-37-190-37-299-181-103
Cash from Financing Activity +-29157-252926116
Net Cash Flow523-142232-44

Free Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow70.0038.00124.00176.00149.00131.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days615774757885
Inventory Days595775635980
Days Payable11495104615662
Cash Conversion Cycle619467680103
Working Capital Days253960645785
ROCE %38%29%24%18%18%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters68.56%68.56%68.56%68.56%68.46%68.44%68.44%68.44%68.35%68.34%68.32%68.32%
FIIs8.46%9.13%9.03%8.51%8.84%8.63%7.46%6.12%5.74%4.14%4.02%3.83%
DIIs12.87%12.77%12.29%13.02%14.15%14.08%15.09%17.71%17.68%18.06%17.74%16.87%
Public10.10%9.54%10.12%9.91%8.55%8.85%9.01%7.73%8.23%9.45%9.90%10.98%
No. of Shareholders65,83176,49492,09998,56595,66497,08196,63495,37195,2001,00,42398,8591,00,475

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Small Cap Fund2,016,7980.64145.68407,2152024-12-27395.27%
UTI Flexi Cap Fund1,915,7520.54138.38407,2152024-12-27370.45%
SBI Flexi Cap Fund1,648,0080.64119.04407,2152024-12-27304.7%
Canara Robeco Small Cap Fund1,067,2930.9385.29407,2152024-12-27162.1%
UTI Small Cap Fund407,2150.8529.42407,2152024-12-270%
Bandhan Focused Equity Fund228,9331.2318.3407,2152024-12-27-43.78%
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan143,5970.210.37407,2152024-12-27-64.74%
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan143,5970.210.37407,2152024-12-27-64.74%
Nippon India Nifty Smallcap 250 Index Fund12,0150.10.96407,2152024-12-27-97.05%
SBI Tax Advantage Fund - Series III7,0001.550.51407,2152024-12-27-98.28%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)23.6719.4617.8115.5613.42
Diluted EPS (Rs.)23.6219.3817.7015.4713.23
Cash EPS (Rs.)34.5630.6826.1919.7316.22
Book Value[Excl.RevalReserv]/Share (Rs.)189.65165.93146.2578.7256.39
Book Value[Incl.RevalReserv]/Share (Rs.)189.65165.93146.2578.7256.39
Revenue From Operations / Share (Rs.)331.35300.22269.36136.60118.23
PBDIT / Share (Rs.)46.5641.4335.5025.4721.37
PBIT / Share (Rs.)35.6330.0226.7721.0718.05
PBT / Share (Rs.)32.1225.9724.4720.4917.35
Net Profit / Share (Rs.)23.6219.2717.4615.3412.90
NP After MI And SOA / Share (Rs.)23.6619.4517.7415.4512.86
PBDIT Margin (%)14.0513.7913.1718.6418.07
PBIT Margin (%)10.759.999.9315.4215.26
PBT Margin (%)9.698.659.0815.0014.67
Net Profit Margin (%)7.126.416.4811.2210.91
NP After MI And SOA Margin (%)7.136.476.5811.3010.87
Return on Networth / Equity (%)12.4711.7112.1319.6222.80
Return on Capital Employeed (%)17.1516.2215.3126.6128.38
Return On Assets (%)8.317.847.7714.2913.83
Long Term Debt / Equity (X)0.030.030.000.000.11
Total Debt / Equity (X)0.100.080.010.000.21
Asset Turnover Ratio (%)1.250.811.441.361.67
Current Ratio (X)1.992.082.072.362.19
Quick Ratio (X)1.321.541.421.731.80
Inventory Turnover Ratio (X)5.223.666.985.926.53
Dividend Payout Ratio (NP) (%)0.002.562.813.164.05
Dividend Payout Ratio (CP) (%)0.001.611.882.463.22
Earning Retention Ratio (%)0.0097.4497.1996.8495.95
Cash Earning Retention Ratio (%)0.0098.3998.1297.5496.78
Interest Coverage Ratio (X)13.2810.2415.4444.2030.49
Interest Coverage Ratio (Post Tax) (X)7.745.768.6027.6219.41
Enterprise Value (Cr.)3801.343233.014985.625300.000.00
EV / Net Operating Revenue (X)2.081.953.367.470.00
EV / EBITDA (X)14.7814.1525.5140.080.00
MarketCap / Net Operating Revenue (X)2.041.983.397.600.00
Retention Ratios (%)0.0097.4397.1896.8395.94
Price / BV (X)3.563.596.2513.180.00
Price / Net Operating Revenue (X)2.041.983.397.600.00
EarningsYield0.030.030.010.010.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Rossari Biotech Ltd as of December 30, 2024 is: 848.42

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 30, 2024, Rossari Biotech Ltd is Undervalued by 6.45% compared to the current share price 797.00

Intrinsic Value of Rossari Biotech Ltd as of December 30, 2024 is: 958.44

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 30, 2024, Rossari Biotech Ltd is Undervalued by 20.26% compared to the current share price 797.00

Last 5 Year EPS CAGR: 12.97%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 21.17%, which is a positive sign.
  2. The company has higher reserves (662.29 cr) compared to borrowings (62.43 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (304.67 cr) and profit (119.33 cr) over the years.
  1. The stock has a high average Working Capital Days of 55.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 55.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
    1. Net Profit Margin: 7.12%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 17.15% (Industry Average ROCE: 14.09%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 12.47% (Industry Average ROE: 10.82%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.74
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.32
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 31.8 (Industry average Stock P/E: 57.71)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.1
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Rossari Biotech Ltd. is a Public Limited Listed company incorporated on 10/08/2009 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH2009PLC194818 and registration number is 194818. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company’s Total Operating Revenue is Rs. 1072.84 Cr. and Equity Capital is Rs. 11.01 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Chemicals - Speciality - Others201 A-B, 2nd Floor, Akruti Corporate Park, Mumbai Maharashtra 400078investors@rossari.com
http://www.rossari.com
Management
NamePosition Held
Mr. Edward MenezesExecutive Chairman
Mr. Sunil ChariManaging Director
Mr. Aseem DhruIndependent Director
Maj.Gen.(Retd.) Sharabh PachoryIndependent Director
Ms. Aparna SharmaIndependent Director
Ms. Esha AchanIndependent Director

FAQ

What is the latest intrinsic value of Rossari Biotech Ltd?

The latest intrinsic value of Rossari Biotech Ltd as on 30 December 2024 is ₹848.42, which is 6.45% higher than the current market price of ₹797.00. The stock has a market capitalization of 4,412 Cr. and recorded a high/low of 973/657 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,107 Cr and total liabilities of ₹1,711 Cr.

What is the Market Cap of Rossari Biotech Ltd?

The Market Cap of Rossari Biotech Ltd is 4,412 Cr..

What is the current Stock Price of Rossari Biotech Ltd as on 30 December 2024?

The current stock price of Rossari Biotech Ltd as on 30 December 2024 is 797.

What is the High / Low of Rossari Biotech Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Rossari Biotech Ltd stocks is 973/657.

What is the Stock P/E of Rossari Biotech Ltd?

The Stock P/E of Rossari Biotech Ltd is 31.8.

What is the Book Value of Rossari Biotech Ltd?

The Book Value of Rossari Biotech Ltd is 202.

What is the Dividend Yield of Rossari Biotech Ltd?

The Dividend Yield of Rossari Biotech Ltd is 0.06 %.

What is the ROCE of Rossari Biotech Ltd?

The ROCE of Rossari Biotech Ltd is 18.1 %.

What is the ROE of Rossari Biotech Ltd?

The ROE of Rossari Biotech Ltd is 13.2 %.

What is the Face Value of Rossari Biotech Ltd?

The Face Value of Rossari Biotech Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Rossari Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE